ATB-346: Phase I data

Data from Phase I trials showed that once-daily 250 mg oral ATB-346 for 14 days was well tolerated. Additionally, Antibe said once-daily 75-250 mg doses of ATB-346 inhibited COX for up to 24 hours aft...